Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC

TOP - August 2018, Vol 11, No 2 - Colorectal Cancer


Almost 66% of patients who had previously received treatment for metastatic co­lorectal cancer (mCRC) and DNA mismatch repair deficiency (dMMR) derived clinical benefit from monotherapy with nivolumab (Opdivo), long-term follow-up from a prospective clinical trial showed. After a median follow-up of almost 2 years, 34% of 74 evaluable patients had objective responses, including 7 complete responses.

An additional 31% of patients had stable disease. The duration of response was as high as 31.6 months, and 66% of responses lasted ≥12 months. Furthermore, most patients (70%-80%) were alive at 18 months, as reported at the 2018 Gastrointestinal Cancers Symposium.

“Nivolumab continued to provide durable clinical benefit with long-term follow-up in previously treated patients with DNA mismatch repair deficiency and microsatellite instability-high [MSI-H] metastatic co­lorectal cancer,” said Michael J. Overman, MD, Committee Chair, Department of Gastrointestinal Medical Oncology, Pharmacy & Therapeutics Committee, M.D. Anderson Cancer Center, Houston, who presented the results.

“We observed durable clinical benefit with deepening of responses, regardless of prior chemotherapy with a fluoropyrimidine, oxaliplatin, and irinotecan.”


The CheckMate-142 clinical trial focused on a subgroup of patients with mCRC associated with dMMR and MSI-H tumors, which account for about 4% of all mCRC. The trial’s design followed preliminary evidence of meaningful clinical benefit in that subgroup. A preliminary analysis of data from the study after 13 months of follow-up showed an objective response rate (ORR) of 32%, and 75% of the patients were alive at 1 year (Overman MJ, et al. Lancet Oncol. 2017;18:1182-1191).

The FDA granted accelerated approval to nivolumab based on a notable clinical benefit in a subset of patients who progressed after receiving the standard first-line chemotherapy with fluoropyrimidine, oxaliplatin, and irinote­can. Dr Overman presented an updated analysis of the CheckMate-142 study.

All patients had received ≥1 lines of systemic therapy. The 74 patients consisted of 53 whose treatment history included exposure to the chemotherapy regimen, and 21 who did not receive all 3 drugs.

Of these patients (median age, 52.5 years), 45% had stage IV mCRC, a majority had BRAF or KRAS mutations, and 38% had a history of Lynch syndrome.

After a median follow-up of 21 months, the ORR had increased slightly from 32% at 13 months to 34%. The clinical benefit rate was 64%, consisting of 7 complete responses (9%), 18 partial responses (24%), and stable disease in 23 patients (31%). An increase in complete responses (2 at 13 months vs 7 at 21 months) and a decrease in partial responses (22 at 13 months vs 18 at 21 months) indicated a deepening of response over time.

The median duration of response had yet to be reached, and the median duration of stable disease was 8.3 months.

“The median time to response was approximately 2.8 months across all subgroups, and clinical benefit was observed across all subgroups,” Dr Overman said. “Overall, 60% of patients had some reduction in tumor burden from baseline with nivolu­mab monotherapy.”

The study population had a median progression-free survival (PFS) of 6.6 months and did not differ between the 2 subgroups specified for the analysis. The PFS at 12 and 18 months was 44%, which was slightly higher in patients without exposure to all 3 chemotherapies (52%) compared with patients with a history of the chemotherapy regimen (41%).

Overall survival (OS) was 60% at 12 months and 54.9% at 18 months. The subgroup analysis showed a median OS of 68% at 12 months and 66% at 18 months for patients with exposure to all 3 chemotherapies. Corresponding rates for patients without exposure to all 3 drugs were 81% at 12 months and 70% at 18 months. No patient who responded to treatment had died as of the data cutoff.

Overall, 75% of patients had treatment-related adverse events, reaching grade 3 or 4 severity in 20% of patients, and 8% of patients discontinued treatment because of adverse events. The most common adverse events (all grades) were fatigue (23%), diarrhea (22%), pruritus (16%), lipase increase (12%, including 8% grade 3 or 4), and rash (11%).

Related Items
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights, Colorectal Cancer
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Colorectal Cancer
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Charlie Dawson
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
Wayne Kuznar
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Colorectal Cancer
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
Charles Bankhead
Web Exclusives published on April 9, 2018 in Emerging Therapies
New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia
Charles Bankhead
Web Exclusives published on April 9, 2018 in Leukemia
Last modified: July 22, 2021